van Eekelen R, Wang R, Danhof NA, et al. - Researchers sought to determine the agent that is most cost-effective for ovarian stimulation (OS) in terms of net benefit for couples with unexplained subfertility undergoing IUI. A decision-analytic model was created based on a decision tree that follows couples with unexplained subfertility from the initiation of IUI-OS to a protocoled maximum of six cycles, considering couples receive four cycles on average within 1 year. Clomiphene citrate (CC) was identified to be linked with the lowest cumulative live birth rate over 4 IUI-OS cycles conducted within 1 year (29.4%), followed by Letrozole (32.0%) and gonadotrophins (34.5%). Overall findings suggest that in terms of net benefit, CC, Letrozole and gonadotrophins are the most cost-effective option in settings where a live birth is valued at €3000 or less, between €3000 and €55 000 and above €55 000, respectively.